BOT17X-t

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameBOT17X-t

Drug Alias NameOncoluthera177Lu-PDGF-beta-receptor binding VHH nanobody (BiOrion Technologies)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionPlatelet-derived growth factor receptor beta modulators

TargetsPlatelet-derived growth factor receptor beta

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBiorion Technologies

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiorion Technologies

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A